NFKB2 and prostate carcinoma: Importantly, these data do not positively contribute to the prognosis since the overexpression of one of the NF-κB proteins can be either favourable or unfavourable in different tumours [36,37,38,39,40] as happens for p52/NF-κB2 in melanoma or renal and colorectal cancers, respectively (https://www.proteinatlas.org) or for the tumour suppressor TP53 in endometrial cancer (favourable) and prostate cancer (unfavourable) [41].